Free Trial

Maxwell Skor Analyst Performance

Analyst at Morgan Stanley

Maxwell Skor is a stock analyst at Morgan Stanley in the medical sector, covering 5 publicly traded companies. Over the past year, Maxwell Skor has issued 5 stock ratings, including buy and hold recommendations. While full access to Maxwell Skor's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Maxwell Skor's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
60.00% 3 Buy Ratings
Companies Covered
5 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy60.0%3 ratings
Hold40.0%2 ratings
Sell0.0%0 ratings

Out of 5 total stock ratings issued by Maxwell Skor at Morgan Stanley, the majority (60.0%) have been Buy recommendations, followed by 40.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
5 companies

Maxwell Skor, an analyst at Morgan Stanley, currently covers 5 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
5 companies
100.0%

Maxwell Skor of Morgan Stanley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
5 companies
100.0%

Maxwell Skor's Ratings History at Morgan Stanley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Insmed, Inc. stock logo
INSM
Insmed
8/21/2025Boost Price Target$129.45$144.00Equal Weight
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
7/3/2025Initiated Coverage$2.92$12.00Overweight
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
7/3/2025Initiated Coverage$173.10$250.00Overweight
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
5/5/2025Set Price Target$9.06$17.00Equal Weight
TScan Therapeutics, Inc. stock logo
TCRX
TScan Therapeutics
3/14/2025Reiterated Rating$1.81$10.00Overweight